PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

The ability of current tests to predict chronic kidney disease (CKD) complicating diabetes is limited. This study investigated the prognostic utility of a novel blood test, PromarkerD, for predicting future renal function decline in individuals with type 2 diabetes from the CANagliflozin CardioVascu...

Full description

Bibliographic Details
Main Authors:	Kirsten E. Peters, Jialin Xu, Scott D. Bringans, Wendy A. Davis, Timothy M.E. Davis, Michael K. Hansen, Richard J. Lipscombe
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Journal of Clinical Medicine
Subjects:	type 2 diabetes diabetic nephropathy renal decline chronic kidney disease biomarkers risk prediction
Online Access:	https://www.mdpi.com/2077-0383/9/10/3212

Similar Items

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
by: Kirsten E. Peters, et al.
Published: (2023-05-01)

The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
by: Scott Bringans, et al.
Published: (2020-10-01)

Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis.
by: Lauren Fusfeld, et al.
Published: (2022-01-01)

Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis
by: Lauren Fusfeld, et al.
Published: (2022-01-01)

Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
by: Scott D. Bringans, et al.
Published: (2017-03-01)

5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria
by: Xiaofang Tang, et al.
Published: (2019-05-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
by: Daniel Guldager Kring Rasmussen, et al.
Published: (2022-11-01)

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
by: Abhinav Sharma, et al.
Published: (2024-02-01)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
by: Syed Raza Shah, et al.
Published: (2018-09-01)

Peripheral Arterial Stiffness Increases the Risk of Progression of Renal Disease in Type 2 Diabetic Patients
by: Tae Hoon Lim, et al.
Published: (2020-09-01)

Changes in soluble tumor necrosis factor receptor type 1 levels and early renal function decline in patients with diabetes
by: Richard J MacIsaac, et al.
Published: (2019-11-01)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
by: Maria Chiara Pelle, et al.
Published: (2023-07-01)

The usefulness of serum beta-2 microglobulin as a biomarker for evaluating renal function decline in type II diabetes mellitus
by: Zainab A. Hussein, et al.
Published: (2022-03-01)

Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline
by: Qin C, et al.
Published: (2022-09-01)

Diabetic Neuropathy [electronic resource]: Clinical Management/
by: Veves, Aristidis, et al.
Published: (2007)

Predictive factors for non-diabetic nephropathy in diabetic patients. The utility of renal biopsy
by: Sheila Bermejo, et al.
Published: (2016-09-01)

Cognitive decline as the main manifestation of diabetic striatal disease but without involuntary movements: a case report
by: He Li, et al.
Published: (2023-11-01)

Molecular mechanisms underlying hyperglycemia associated cognitive decline
by: Mrinal Gupta, et al.
Published: (2023-06-01)

Sodium Tungstate (NaW) Decreases Reactive Oxygen Species (ROS) Production in Cells: New Cellular Antioxidant
by: Alejandro J. Yañez, et al.
Published: (2023-01-01)

Histopathological Changes on The Kidney and Lung of Experimentally Induced Diabetic Rats
by: Ghada Mohammed Ahmed*, et al.
Published: (2023-01-01)

Diabetic Kidney Disease and Hypertension: A True Love Story
by: Anand Verma, et al.
Published: (2016-03-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Clinical and Pathological Characteristics of Patients With Nonproteinuric Diabetic Nephropathy
by: Dong-Yuan Chang, et al.
Published: (2021-10-01)

Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy
by: Min Sun Choi, et al.
Published: (2021-05-01)

All‐cause and cardiovascular disease mortality in underweight patients with diabetic nephropathy: BioBank Japan cohort
by: Hiroshi Yokomichi, et al.
Published: (2021-08-01)

Explanatory role of sociodemographic, clinical, behavioral, and social factors on cognitive decline in older adults with diabetes
by: Sean M. O’Toole, et al.
Published: (2022-01-01)

Ginger and Diabetic Nephropathy: A Letter to the Editor
by: Mahmoud Rafieian-Kopaei, et al.
Published: (2014-04-01)

Diabetes mellitus: renal osmoregulating function
by: Yu V Natochin, et al.
Published: (2010-06-01)

STUDENT RESEARCH COMMITTEE , SCHOOL OF MEDICINE, SHIRAZ UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES, SHIRAZ, IRAN
by: MOSALAEI MAHNAZ, et al.
Published: (2002-06-01)

The care of the elderly with diabetic nephropathy in conservative treatment
by: Caren da Silva Jacobi, et al.
Published: (2013-09-01)

Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice
by: Young Sun Kang, et al.
Published: (2016-05-01)

Comparison of the Pathological Picture of Experimental Diabetic Nephropathy in Rats at Early (1 month) and Late (8 months) Stages
by: A. Zharikov, et al.
Published: (2019-12-01)

Evaluation of the effectiveness of diabetic nephropathy stage III in patients with type 2 diabetes mellitus therapy with sulodexide
by: V. G. Kadzharyan, et al.
Published: (2013-08-01)

Sarcopenia in diabetic nephropathy: a cross-sectional study
by: Çeliker Meral, et al.
Published: (2018-06-01)

Correlation between Diabetes Mellitus Onset with Diabetic Nephropathy Caseof the In-Patients Treated in RS Muhammadiyah Ahmad Dahlan Kediri
by: Satria Candra Kusuma, et al.
Published: (2019-12-01)

Clinical profile of patients with diabetic nephropathy in a tertiary level hospital in Dhaka, Bangladesh
by: Sheikh MohammedShariful Islam, et al.
Published: (2015-01-01)

Predictors of cognitive decline in older adult type 2 diabetes from the Veterans Affairs Diabetes Trial
by: Mark Zimering, et al.
Published: (2016-09-01)

Impact of vascular risk factors on cognitive decline associated with diabetes mellitus
by: Mirena P. VALKOVA, et al.
Published: (2019-09-01)

An Overview of Diabetic Nephropathy
by: Alp Atasoy, et al.
Published: (2015-03-01)